HALIFAX, Nova Scotia, April 17, 2018 (GLOBE NEWSWIRE) — Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology corporation, is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading independent proxy advisory firms, have recommended that shareholders vote FOR all items submitted for approbation by the shareholders, including the share consolidation for a potential Nasdaq listing and the Corporation’s name change, at the annual and special meeting of shareholders to be held on May 1, 2018.
Immunovaccine Announces Leading Independent Proxy Advisory Firms Recommend Voting for Share Consolidation Related to Potential Nasdaq Listing
by GlobeNewsWire | Apr 17, 2018 | Globe Newswire